However, for adequately treating RA, most drugs primarily focus on attenuating inflammation, and only a few agents target inhibition of osteoclast differentiation, especially inhibition of the RANKL-RANK interaction. The gene discussed is TNFSF11; the disease is rheumatoid arthritis.